A Study to Evaluate Efficacy and Safety of Deucravacitinib in Participants With Alopecia Areata
Part of paid clinical trials in Santa Monica, California.
- Sponsor
- Bristol-Myers Squibb
- Study ID
- NCT05556265
- Phase
- PHASE2
- Status
- Terminated
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 65 Years
- Healthy Volunteers
- Not accepted
Interventions
- Deucravacitinib — DRUGSpecified dose on specified days
- Placebo — OTHERPlacebo was administered.
Study Details
The purpose of this study is to evaluate the efficacy of deucravacitinib versus placebo at Week 24 and safety and tolerability of deucravacitinib versus placebo in adults with alopecia areata.
Key Dates
- Start date
- Nov 8, 2022
- Status verified
- May 2025
- Primary completion
- Jan 6, 2024
- Completion
- May 16, 2024
Study Design
- Enrollment
- 94 participants (actual)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: Deucravacitinib Dose 1
- Experimental: Deucravacitinib Dose 2
- Placebo Comparator: Placebo, followed by Deucravacitinib Dose 1 or Dose 2.
Primary Outcome Measure
Change From Baseline in Severity of Alopecia Tool Score at Week 24 in Placebo-Controlled Treatment Period [ Time Frame: Baseline (Day 1) and Week 24 ]
Locations (12)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Local Institution - 0016 | Santa Monica | California | 90404-2120 | - |
| Local Institution - 0036 | New Haven | Connecticut | 06510 | - |
| Local Institution - 0018 | Tampa | Florida | 33624-2038 | - |
| Local Institution - 0023 | Clinton Township | Michigan | 48038-1137 | - |
| Local Institution - 0024 | New York | New York | 10029-6501 | - |
| Local Institution - 0019 | Chapel Hill | North Carolina | 27516-4061 | - |
| Local Institution - 0011 | Portland | Oregon | 97201-5134 | - |
| Local Institution - 0032 | Pittsburgh | Pennsylvania | 15213-3403 | - |
| Local Institution - 0012 | Austin | Texas | 78759 | - |
| Local Institution - 0013 | Houston | Texas | 77004-8098 | - |
| Local Institution - 0014 | San Antonio | Texas | 78213-2250 | - |
| Local Institution - 0017 | South Jordan | Utah | 84095 | - |
Related coverage on Hipa.ai
- Deucravacitinib Alopecia Areata Trial Shows No Improvement vs. PlaceboDeucravacitinib · Feb 28, 2025 · ClinicalTrials.gov
Find similar trials in Santa Monica, CA
Related Studies
- Regeneron AA Multicenter (Dupilumab)PHASE2 · Recruiting · Emma Guttman · Irvine, California
- Dupilumab in the Treatment of Pediatric Alopecia AreataPHASE2 · Recruiting · Icahn School of Medicine at Mount Sinai · Irvine, California
- A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia AreataPHASE3 · Recruiting · AbbVie · Birmingham, Alabama
- Characterization And Clinical Outcomes of AA Patients Treated With RitlecitinibRecruiting · Pfizer · Montgomery, Alabama